Skip to main content
. 2022 Aug 10;44(2):308–320. doi: 10.1038/s41401-022-00941-3

Fig. 1. Roxadustat reduces LPS-induced intracellular ROS levels in BV-2 cells.

Fig. 1

a BV-2 cells were pre-treated with roxadustat at indicated concentrations for 1 h, then co-treated with 1 μg/mL LPS for another 24 h, followed by determination of cell viability by MTT assay. b, c BV-2 cells were pre-treated with indicated concentrations of roxadustat for 1 h, then co-treated with 1 μg/mL LPS for another 12 h. ROS levels were detected using DCFH-DA. ##P < 0.01; ###P < 0.001 vs. Control group (Ctrl); **P < 0.01 vs. LPS treated group; ns: not significantly different (n = 5), Rox: roxadustat.